Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TNKase: Update

An international, 6,000-patient Phase IIIb ASSENT 3 study will evaluate TNKase with heparin, Lovenox enoxaparin low molecular weight heparin from Aventis S.A.

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE